Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand

The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 10/2010; 107(40):17327-32. DOI: 10.1073/pnas.1008151107
Source: PubMed

ABSTRACT Plasmodium falciparum is responsible for the most severe form of malaria disease in humans, causing more than 1 million deaths each year. As an obligate intracellular parasite, P. falciparum's ability to invade erythrocytes is essential for its survival within the human host. P. falciparum invades erythrocytes using multiple host receptor-parasite ligand interactions known as invasion pathways. Here we show that CR1 is the host erythrocyte receptor for PfRh4, a major P. falciparum ligand essential for sialic acid-independent invasion. PfRh4 and CR1 interact directly, with a K(d) of 2.9 μM. PfRh4 binding is strongly correlated with the CR1 level on the erythrocyte surface. Parasite invasion via sialic acid-independent pathways is reduced in low-CR1 erythrocytes due to limited availability of this receptor on the surface. Furthermore, soluble CR1 can competitively block binding of PfRh4 to the erythrocyte surface and specifically inhibit sialic acid-independent parasite invasion. These results demonstrate that CR1 is an erythrocyte receptor used by the parasite ligand PfRh4 for P. falciparum invasion.

Download full-text


Available from: Wai-Hong Tham, Aug 17, 2015
  • Source
    • "The results showed that HABP 37672, 37736, 37740 and 37744 receptors had the following pattern: neuraminidase-resistant, trypsin-sensitive and chymmotrypsin-sensitive (Fig. 4). It is worth noting that this was the same pattern as that for complement receptor 1 (CR1) which had been identified as PfRh4 protein receptor, the major ligand for invasion via the sialic acid-independent pathway [43] [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmodium falciparum malaria parasite invasion of erythrocytes is an essential step in host infection and the proteins involved in such invasion are the main target in developing an antimalarial vaccine. Secretory organelle-derived proteins (micronemal AMA1 protein and the RON2, 4, and 5 rhoptry neck proteins) have been recently described as components of moving junction complex formation allowing merozoites to move into a newly-created parasitophorous vacuole. This study led to identifying RON5 regions involved in binding to human erythrocytes by using a highly robust, sensitive and specific receptor-ligand interaction assay; it is further shown that the RON5 protein remains highly conserved throughout different parasite strains. It is shown that the binding peptide-erythrocyte interaction is saturable and sensitive to chymotrypsin and trypsin. Invasion inhibition assays using erythrocyte binding peptides showed that the RON5-erythrocyte interaction could be critical for merozoite invasion of erythrocytes. This work provides evidence (for the first time) suggesting a fundamental role for RON5 in erythrocyte invasion.
    Peptides 08/2013; 53. DOI:10.1016/j.peptides.2013.07.028 · 2.61 Impact Factor
  • Source
    • "Together these findings suggest that host serum components are not important in merozoite invasion. Of note, an interaction between the merozoite protein reticulocyte binding homologue 4 (Rh4) and human complement receptor 1 (CR1) on the RBC surface has been implicated in invasion via the sialic-acid independent pathway (Spadafora et al., 2010; Tham et al., 2010). Additionally, a complex between CR1, Rh4 and the serum complement component C4b has recently been described (Tham et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Merozoite invasion of human red blood cells (RBCs) by Plasmodium falciparum is essential for blood stage asexual replication and the development of malaria disease. Despite this, many of the processes involved in invasion are poorly understood. Recent advances have been made in methods to isolate viable merozoites for studies of invasion. The application of these approaches is providing new insights into the kinetics of invasion and merozoite survival, as well as proteins and interactions involved in invasion, and will facilitate the development and testing of anti-merozoite vaccines and the identification of invasion-inhibitory compounds with potential for drug development. This review discusses these recent advances and considers potential avenues for future research.
    International journal for parasitology 12/2012; 43(1). DOI:10.1016/j.ijpara.2012.11.002 · 3.40 Impact Factor
  • Source
    • "Contrary to P. vivax, P. falciparum has long been described as invading RBCs through multiple, alternative pathways, with significant redundancy [98]. The Plasmodium receptors identified on RBCs include glycophorin A [99], glycophorin C [100], glycophorin B [101], and complement receptor 1 [102]. P. falciparum has been shown to invade erythrocytes in both a sialic acid (SA)-dependent and an SAindependent fashion, and to be able to switch reversibly between these two modes of invasion [103]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen's own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
    Current pharmaceutical design 09/2012; 19(2). DOI:10.2174/138161213804070276 · 3.29 Impact Factor
Show more